FLOWERS FOODS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FLOWERS FOODS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $5.26B | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $5.10B | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | $5.09B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $4.81B | Feb 18, 2025 |
| FY2023 | Jan 1, 2022 | $4.33B | Feb 21, 2024 |
| FY2022 | Jan 2, 2021 | $4.39B | Feb 22, 2023 |
| FY2021 | Dec 28, 2019 | $4.12B | Feb 23, 2022 |
| FY2020 | Dec 29, 2018 | $3.95B | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $3.92B | Feb 19, 2020 |
| FY2011 | Dec 31, 2011 | $2.77B | Feb 29, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $5.26B | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $5.10B | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | $5.09B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $4.81B | Feb 18, 2025 |
| FY2021 | Jan 1, 2022 | $983.49M | Feb 23, 2022 |
| FY2021 | Oct 9, 2021 | $1.03B | Feb 23, 2022 |
| FY2021 | Jul 17, 2021 | $1.02B | Feb 23, 2022 |
| FY2021 | Apr 24, 2021 | $1.30B | Feb 23, 2022 |
| FY2021 | Jan 2, 2021 | $1.02B | Feb 23, 2022 |
| FY2021 | Oct 3, 2020 | $989.65M | Feb 23, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $83.83M | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $248.12M | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | $123.42M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $228.39M | Feb 18, 2025 |
| FY2021 | Jan 1, 2022 | $39.32M | Feb 23, 2022 |
| FY2021 | Oct 9, 2021 | $38.85M | Feb 23, 2022 |
| FY2021 | Jul 17, 2021 | $56.36M | Feb 23, 2022 |
| FY2021 | Apr 24, 2021 | $71.66M | Feb 23, 2022 |
| FY2021 | Jan 2, 2021 | $55.82M | Feb 23, 2022 |
| FY2021 | Oct 3, 2020 | $44.35M | Feb 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $173.98M | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $348.29M | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | $172.87M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $303.22M | Feb 18, 2025 |
| FY2023 | Jan 1, 2022 | $294.92M | Feb 21, 2024 |
| FY2022 | Jan 2, 2021 | $321.49M | Feb 22, 2023 |
| FY2021 | Dec 28, 2019 | $225.43M | Feb 23, 2022 |
| FY2020 | Dec 29, 2018 | $212.34M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $161.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $264.90M | Feb 20, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $9.3K | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $5.10M | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | $5.90M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $6.10M | Feb 18, 2025 |
| FY2023 | Jan 1, 2022 | $5.60M | Feb 21, 2024 |
| FY2022 | Jan 2, 2021 | $4.00M | Feb 22, 2023 |
| FY2021 | Dec 28, 2019 | $4.30M | Feb 23, 2022 |
| FY2020 | Dec 29, 2018 | $4.90M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $2.40M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $3.00M | Feb 20, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $2.08B | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $2.00B | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | $2.12B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.85B | Feb 18, 2025 |
| FY2023 | Jan 1, 2022 | $1.72B | Feb 21, 2024 |
| FY2022 | Jan 2, 2021 | $1.69B | Feb 22, 2023 |
| FY2021 | Dec 28, 2019 | $1.58B | Feb 23, 2022 |
| FY2020 | Dec 29, 2018 | $1.51B | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $1.51B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $1.47B | Feb 20, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $446.20M | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $412.66M | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | $349.35M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $360.89M | Feb 18, 2025 |
| FY2023 | Jan 1, 2022 | $344.61M | Feb 21, 2024 |
| FY2022 | Jan 2, 2021 | $454.46M | Feb 22, 2023 |
| FY2021 | Dec 28, 2019 | $366.95M | Feb 23, 2022 |
| FY2020 | Dec 29, 2018 | $295.89M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $297.39M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $356.56M | Feb 20, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $127.11M | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $132.09M | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | $129.08M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $169.07M | Feb 18, 2025 |
| FY2023 | Jan 1, 2022 | $135.96M | Feb 21, 2024 |
| FY2022 | Jan 2, 2021 | $97.93M | Feb 22, 2023 |
| FY2021 | Dec 28, 2019 | $103.69M | Feb 23, 2022 |
| FY2020 | Dec 29, 2018 | $99.42M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $75.23M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $101.73M | Feb 20, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $4.18B | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $3.40B | Feb 25, 2026 |
| FY2024 | Dec 30, 2023 | $3.43B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $3.31B | Feb 21, 2024 |
| FY2022 | Jan 1, 2022 | $3.25B | Feb 22, 2023 |
| FY2021 | Jan 2, 2021 | $3.32B | Feb 23, 2022 |
| FY2020 | Dec 28, 2019 | $3.18B | Feb 24, 2021 |
| FY2019 | Dec 29, 2018 | $2.85B | Feb 19, 2020 |
| FY2018 | Dec 30, 2017 | $2.66B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $2.76B | Feb 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.30B | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $1.41B | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | $1.35B | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $1.44B | Feb 25, 2026 |
| FY2024 | Jan 1, 2022 | $1.41B | Feb 18, 2025 |
| FY2023 | Jan 2, 2021 | $1.37B | Feb 21, 2024 |
| FY2022 | Dec 28, 2019 | $1.26B | Feb 22, 2023 |
| FY2021 | Dec 29, 2018 | $1.26B | Feb 23, 2022 |
| FY2020 | Dec 30, 2017 | $1.25B | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | $1.21B | Feb 19, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.05B | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $679.90M | Feb 25, 2026 |
| FY2024 | Dec 30, 2023 | $677.80M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $545.24M | Feb 21, 2024 |
| FY2022 | Jan 1, 2022 | $545.24M | Feb 22, 2023 |
| FY2021 | Jan 2, 2021 | $545.24M | Feb 23, 2022 |
| FY2020 | Dec 28, 2019 | $545.24M | Feb 24, 2021 |
| FY2020 | Dec 29, 2018 | $545.38M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $464.78M | Feb 19, 2020 |
| FY2019 | Jan 14, 2017 | $801.0K | Feb 19, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $852.07M | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $977.56M | Feb 25, 2026 |
| FY2024 | Dec 30, 2023 | $932.47M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.00B | Feb 21, 2024 |
| FY2022 | Jan 1, 2022 | $962.38M | Feb 22, 2023 |
| FY2021 | Jan 2, 2021 | $932.09M | Feb 23, 2022 |
| FY2020 | Dec 28, 2019 | $947.05M | Feb 24, 2021 |
| FY2019 | Dec 29, 2018 | $945.41M | Feb 19, 2020 |
| FY2018 | Dec 30, 2017 | $919.66M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $910.52M | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $12.10M | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $5.01M | Feb 25, 2026 |
| FY2024 | Dec 30, 2023 | $22.53M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $165.13M | Feb 21, 2024 |
| FY2022 | Jan 1, 2022 | $185.87M | Feb 22, 2023 |
| FY2021 | Jan 2, 2021 | $307.48M | Feb 23, 2022 |
| FY2020 | Dec 28, 2019 | $11.04M | Feb 24, 2021 |
| FY2019 | Dec 29, 2018 | $25.31M | Feb 19, 2020 |
| FY2018 | Dec 30, 2017 | $5.13M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $6.41M | Feb 21, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.76B | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $1.02B | Feb 25, 2026 |
| FY2024 | Dec 30, 2023 | $1.05B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $891.84M | Feb 21, 2024 |
| FY2022 | Jan 1, 2022 | $890.61M | Feb 22, 2023 |
| FY2021 | Jan 2, 2021 | $960.10M | Feb 23, 2022 |
| FY2020 | Dec 28, 2019 | $866.51M | Feb 24, 2021 |
| FY2019 | Dec 29, 2018 | $979.59M | Feb 19, 2020 |
| FY2018 | Dec 30, 2017 | $805.09M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $808.73M | Feb 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 0 | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | 1 | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 18, 2025 |
| FY2021 | Jan 1, 2022 | 0 | Feb 23, 2022 |
| FY2021 | Oct 9, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Jul 17, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Apr 24, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Jan 2, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Oct 3, 2020 | 0 | Feb 23, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 0 | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | 1 | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 18, 2025 |
| FY2021 | Jan 1, 2022 | 0 | Feb 23, 2022 |
| FY2021 | Oct 9, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Jul 17, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Apr 24, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Jan 2, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Oct 3, 2020 | 0 | Feb 23, 2022 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $209.31M | Feb 25, 2026 |
| FY2025 | Dec 28, 2024 | $203.03M | Feb 25, 2026 |
| FY2025 | Dec 30, 2023 | $195.22M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $186.50M | Feb 18, 2025 |
| FY2023 | Jan 1, 2022 | $175.90M | Feb 21, 2024 |
| FY2022 | Jan 2, 2021 | $167.27M | Feb 22, 2023 |
| FY2021 | Dec 28, 2019 | $159.99M | Feb 23, 2022 |
| FY2020 | Dec 29, 2018 | $150.21M | Feb 24, 2021 |
| FY2019 | Dec 30, 2017 | $140.98M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $131.07M | Feb 20, 2019 |